Key result
Patients with heart failure with mid-range ejection fraction (HFmrEF) exhibited intermediate clinical characteristics, cardiac event rates, and all-cause mortality compared to HFrEF and HFpEF.
Why the study?
Heart failure with mid-range ejection fraction (HFmrEF; LVEF 40-49%) had recently been focused upon, but its clinical features and outcomes had not yet been fully examined.
Population
2103 decompensated heart failure patients discharged from Fukushima Medical University Hospital
Comparison
HFrEF (n = 629) vs HFmrEF (n = 313) vs HFpEF (n = 1161)
Design
Single-center prospective observational study
Follow-up
Until 2018
Authors
Loading...
HFmrEF shows intermediate prognosis; supports distinct phenotyping but leaves open tailored therapy needs.
Observational (n=2,103)
No
Patients with heart failure with mid-range ejection fraction (HFmrEF) exhibit distinct clinical characteristics and an intermediate prognosis compared to those with HFrEF and HFpEF.
Yoshihisa et al. (2019) conducted an observational in Decompensated heart failure (n=2,103). Heart failure with mid-range ejection fraction (HFmrEF) vs. Heart failure with reduced (HFrEF) and preserved (HFpEF) ejection fraction was evaluated on Cardiac events (worsened heart failure and cardiac death) and all-cause death. Patients with heart failure with mid-range ejection fraction (HFmrEF) exhibited intermediate clinical characteristics, cardiac event rates, and all-cause mortality compared to HFrEF and HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: